LI KANG BIOMEDICAL Co. Ltd.

LI KANG BIOMEDICAL Co. Ltd.

TTPEX:6242
30.85
TWD
-0.05
(-0.16%)
2.39EPS
15.15P/E
1.16BMarket Cap
LI KANG BIOMEDICAL Co. Ltd.
TPEX:6242
(Taipei Exchange)

Recent

price

30.85

P/E

ratio

15.15

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
13.07
31.59
35.62
9.17
13.97
16.44
16.25
17.89
17.87
17.43
16.47
13.96
24.68
23.48
18.22
18.52
18
Revenue per Share
-5.92
-8.9
-5.12
-2.39
-1.43
1.91
2.22
4.82
2.77
2.6
2.5
1.86
4.04
4.14
2.48
2.64
2.4
Basic EPS, GAAP
-2.3
-8.55
-5.63
-0.93
1.83
-11.23
3.84
3.87
1.01
3.33
2.88
2.02
5.57
3.49
0.02
-7.46
-5.58
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.04
1.04
2
2
1.6
2.24
1.2
1.74
2.56
2
- -
Dividend per Share
4.08
17.77
12.25
3.5
8.2
10.11
12.29
16.08
16.84
17.44
18.33
17.75
20.56
22.72
26.9
27.39
26.5
Book Value per Share
4.08
17.77
12.25
3.4
8.14
10.07
12.27
16.06
16.83
17.43
18.33
17.74
20.5
22.69
26.84
27.37
26.48
Tangible Book Value per Share
17
5
7
26
18
28
28
28
28
28
28
28
28
27
31
32
32
Basic Weighted Avg Shares
229
168
247
237
256
456
451
496
496
483
457
387
684
629
566
589
573
Sales/Revenue/Turnover
-33.43
-33
-8.44
-20.14
2.99
11.62
14.78
17.09
18.36
18.27
17.72
14.79
20.07
21.19
15.92
16.68
15.21
Operating Margin (%)
9
1
2
3
2
12
19
19
18
18
15
13
11
12
12
9
7
Depreciation Expense
-104
-47
-35
-62
-26
53
62
134
77
72
69
51
112
111
77
84
76
Net Income, GAAP
- -
- -
- -
- -
- -
- -
3.3
1.94
20.29
21.15
20.33
18.97
20.39
20.23
22.35
19.44
18.34
Effective Tax Rate (%)
-45.32
-28.16
-14.38
-26.08
-10.23
11.6
13.65
26.97
15.48
14.9
15.17
13.29
16.38
17.64
13.62
14.23
13.32
Profit Margin (%)
84
81
62
17
203
21
60
159
114
140
170
128
191
246
419
85
10
Working Capital
- -
- -
- -
- -
- -
124
85
63
49
41
33
25
- -
87
86
53
54
LT Debt
104
123
85
24
227
280
341
446
467
483
508
492
570
630
856
871
843
Total Equity
- -
- -
- -
- -
- -
16.04
14.73
16.93
13.4
12.61
11.35
8.23
18.81
15.45
8.09
7.92
7.07
Return on Invested Capital (%)
- -
- -
- -
- -
- -
16.01
14.55
27.63
14.52
13.51
12.64
9.45
20.02
16.89
9.16
8.49
7.69
Return on Capital (%)
-89.05
-41.61
-34.12
-113.4
-20.81
20.82
19.81
34.01
16.82
15.16
13.97
10.28
21.11
18.5
10.37
9.71
9.12
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
95
85
107
LT Borrowings
- -
- -
- -
LT Finance Leases
53
53
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
1,248
1,185
1,156

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
253
249
252
Cash, Cash Equivalents & STI
190
183
178
Accounts Receivable, Net
9
8
8
Inventories
46
52
59
Total Current Liabilities
168
158
241
Payables & Accruals
- -
- -
- -
ST Debt
95
85
107
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.66%
12.16%
1.82%
Free Cash Flow
-3,638.39%
-7,278.41%
-36,399.39%
Net Income, GAAP
15.06%
13.89%
8.83%
Sales/Revenue/Turnover
4.84%
9.51%
4.19%
Total Cash Common Dividend
- -
16.83%
-20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
123
151
127
164
566
2025
135
165
118
172
589
2026
122
162
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.67
0.54
0.82
2.48
2025
0.53
0.81
0.42
0.87
2.64
2026
0.33
0.77
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.56
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
- -
Business
Li Kang Biomedical Co., Ltd. primarily engages in the manufacturing and sale of supplement products, cosmeceuticals, and hygienic drink products. The company operates in traditional Chinese medicine-related segments, developing and promoting hygienic tea drinks with a specialization in Chinese herbal medicine ingredients. It also provides services in the management and consulting of tourism factory businesses and operates telemarketing services as part of its diversified business model. Li Kang Biomedical has cultivated a unique business model by integrating manufacturing and tourism service industries, notably through its "Tourism Factory" business divisions such as Li Kang Cultural Hall for Chinese Herbs Industry and Li Kang Tourism Factory of Health and Regime. The company further emphasizes channel operations through decentralized channels including tourism factories, telemarketing, and chain stores of traditional Chinese medicine pharmacies. Founded in 1982 and headquartered in Tainan City, Taiwan, Li Kang Biomedical was formerly known as BAFO Technologies Corporation and changed its name in 2014 to better reflect its core business focus. The company has expanded partnerships in recent years, including a significant collaboration with Intellego to distribute disinfection industry products in China and Asia under a USD 360 million deal spanning five years, illustrating its strategic expansion into health-related product sectors in the Asia region. Li Kang Biomedical targets markets primarily within Taiwan and broader Asia, applying its expertise in supplement, cosmeceutical, and herbal hygienic beverages toward consumers interested in health and wellness, as well as service-based tourism and telemarketing sectors. The company employs around 122 people and reported revenue of approximately TWD 565.52 million in 2024. Its ongoing business developments emphasize integrating health product manufacturing with tourism-based experiential marketing and expanding into new markets and product lines through partnerships and strategic sales channels, notably within traditional Chinese medicine and health-related consumer products. Overall, Li Kang Biomedical operates in consumer health, cosmetics, and tourism management sectors, combining product manufacturing with innovative service models to leverage the growing interest in Chinese herbal medicine and health tourism in Taiwan and Asia. Recent major changes include its name change in 2014 reflecting its strategic reorientation, and expanding regional partnerships to grow its product footprint in the disinfection and hygiene product markets across China and Asia.